CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, ...

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ... detention center Transgender issues are a strength for Trump ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Zepbound's prescription ... struggles with supply issues in 2024. CVS's pharmacy benefit management unit, the largest in the U.S., said it would drop Zepbound coverage from July 1, but keep ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Zepbound’s prescription ... struggles with supply issues in 2024. CVS’s pharmacy benefit management unit, the largest in the U.S., said it would drop Zepbound coverage from July 1, but keep ...

Insurers reported 91 per cent increase in claims for weight-loss drugs last year after Wegovy launched in Canada ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...